DHR logo

Danaher Corporation Stock Price

NYSE:DHR Community·US$156.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 115 Fair Values set on narratives written by author

DHR Share Price Performance

US$227.39
-8.45 (-3.58%)
US$254.20
Fair Value
US$227.39
-8.45 (-3.58%)
10.5% undervalued intrinsic discount
US$254.20
Fair Value
Price US$227.39
AnalystConsensusTarget US$254.20

DHR Community Narratives

AnalystConsensusTarget·
Fair Value US$254.2 10.5% undervalued intrinsic discount

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

0users have liked this narrative
0users have commented on this narrative
61users have followed this narrative

Updated Narratives

DHR logo

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

Fair Value: US$254.2 10.5% undervalued intrinsic discount
61 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with limited growth.

1 Risk
1 Reward

Danaher Corporation Key Details

US$24.3b

Revenue

US$9.8b

Cost of Revenue

US$14.5b

Gross Profit

US$11.0b

Other Expenses

US$3.5b

Earnings

Last Reported Earnings
Sep 26, 2025
Next Reporting Earnings
n/a
4.96
59.59%
14.43%
33.0%
View Full Analysis

About DHR

Founded
1969
Employees
62000
CEO
Rainer Blair
WebsiteView website
www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Recent DHR News & Updates

Recent updates

No updates